A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia
Abstract Background Dyslipidemia is a known risk factor for cardiovascular disease. While statins are the primary treatment, some individuals require additional lipid-lowering therapies, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Alirocumab and evolocumab have shown ef...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Portfolio
2024-10-01
|
| coleção: | Communications Medicine |
| Acesso em linha: | https://doi.org/10.1038/s43856-024-00611-x |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|